"10.1371_journal.pone.0087316","plos one","2014-01-29T00:00:00Z","Moonhee Lee; Sujaatha Narayanan; Edith G McGeer; Patrick L McGeer","Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/BMT Program of BC, Division of Hematology, Vancouver General Hospital, BC Cancer Agency, Vancouver, British Columbia, Canada","Conceived and designed the experiments: EM PM. Performed the experiments: MHL. Analyzed the data: MHL EM PM. Wrote the paper: MHL EGM PLM. Arranged for blood collection and wrote up the clinical aspects: SN.","PLM, EGM and MH hold shares in Aurin Biotech Inc. The company has applied for use patents to treat several diseases involving aberrant complement activation, including PNH. With regard to conflict of interest, the use patent applications representing a potential conflict of interest are: US patent application 13/541,535 Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex (Publication No. US-2013-0035392-A1) and PCT patent application PCT/IB2012/053608 by the same title. This does not alter the authors adherence to all PLOS ONE policies on sharing data and materials.","2014","01","Moonhee Lee","ML",4,TRUE,2,1,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
